Benzodiazepine Screen, Blood from HealthLabs

The published purchase price is $49. The provider also publishes HSA or FSA eligibility and cancellation terms.

The Benzodiazepine Screen, Blood lists fourteen benzodiazepine compounds and metabolites detected in a blood sample collected at an in-person laboratory visit.

This blood screen is for detecting benzodiazepine use: it reports fourteen benzodiazepine compounds and their metabolites from a blood sample drawn at an in-person lab visit.

The provider documents result delivery for Benzodiazepine Screen, Blood, but the current evidence does not confirm individualized interpretation, reference guidance, or clinician follow-up.

Benzodiazepine Screen, Blood documents what is collected and measured. The documented specimen is blood. The current evidence does not identify one confirmed analytical method for every included measurement.

The documented ordering route includes an in-person laboratory visit. Collection uses blood. The published turnaround is Product states within 24 hours in one section and 1 to 3 business days in another.

The current record does not identify a product-specific privacy policy covering retention, deletion, research, sharing, and marketing practices.

The provider publishes an exact first-party product page, a published price, the specimen, and the included scope. The record still does not confirm analytical method, parent and metabolite reporting, cutoffs, units, sensitivity, confirmation, collection type, and laboratory identity are unresolved.